DelveInsight’s, “TIGIT Inhibitor Pipeline Insight 2025” report provides comprehensive insights about 14+ companies and 18+ pipeline drugs in TIGIT Inhibitor pipeline landscape. It covers the TIGIT Inhibitor Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TIGIT Inhibitor Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the TIGIT Inhibitor Pipeline? Click here to explore the therapies and trials making headlines @ TIGIT Inhibitor Pipeline Outlook Report
Key Takeaways from the TIGIT Inhibitor Pipeline Report
- On 17 September 2025, AstraZeneca announced a Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer.
- DelveInsight’s TIGIT Inhibitor Pipeline report depicts a robust space with 14+ active players working to develop 18+ pipeline therapies for TIGIT Inhibitor treatment.
- The leading TIGIT Inhibitor Companies such as Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Tasrif Pharmaceutical, Y-Biologics, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, and Bio-Thera Solutions and others.
- Promising TIGIT Inhibitor Therapies such as Zimberelimab, Domvanalimab, Pembrolizumab, Quavonlimab, Vibostolimab, Trastuzumab deruxtecan, Rilvegostomig and others.
Want to know which companies are leading innovation in TIGIT Inhibitor? Dive into the full pipeline insights @ TIGIT Inhibitor Clinical Trials Assessment
The TIGIT Inhibitor Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The TIGIT Inhibitor Pipeline Report also highlights the unmet needs with respect to the TIGIT Inhibitor.
TIGIT Inhibitor Overview
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain. It is expressed on activated and memory T cells, NK cells, and Tregs. Binding to either of its two ligands on APCs, CD155 (PVR: poliovirus receptor) and CD112 (PVRL2, nectin-2), prevents their maturation and confers a tolerogenic phenotype.
TIGIT Inhibitor Emerging Drugs Profile
- Tiragolumab: Genentech
Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body’s immune response. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell antitumor activity.
- Ociperlimab: BeiGene
Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact IgG Fc binding region for optimal antibody-mediated anti-tumor activity. Ociperlimab binds to TIGIT and blocks its interactions with the poliovirus receptor (CD155) and poliovirus receptor-related 2 (CD112) ligands on tumor cells, resulting in activation of T cell mediated antitumor immune responses.
If you’re tracking ongoing TIGIT Inhibitor Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ TIGIT Inhibitor Treatment Drugs
The TIGIT Inhibitor Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of TIGIT Inhibitor with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for TIGIT Inhibitor Treatment.
- TIGIT Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- TIGIT Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the TIGIT Inhibitor market.
TIGIT Inhibitor Companies
Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Tasrif Pharmaceutical, Y-Biologics, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, and Bio-Thera Solutions and others.
TIGIT Inhibitor Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as,
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
TIGIT Inhibitor Products have been categorized under various Molecule types such as,
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
From emerging drug candidates to competitive intelligence, the TIGIT Inhibitor Pipeline Report covers it all – check it out now @ TIGIT Inhibitor Market Drivers and Barriers, and Future Perspectives
Scope of the TIGIT Inhibitor Pipeline Report
- Coverage- Global
- TIGIT Inhibitor Companies- Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Tasrif Pharmaceutical, Y-Biologics, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, and others.
- TIGIT Inhibitor Therapies- Zimberelimab, Domvanalimab, Pembrolizumab, Quavonlimab, Vibostolimab, Trastuzumab deruxtecan, Rilvegostomig, and others.
- TIGIT Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- TIGIT Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the TIGIT Inhibitor Treatment landscape in this detailed analysis @ TIGIT Inhibitor Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- TIGIT Inhibitors: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- TIGIT Inhibitors – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tiragolumab: Genentech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MK-7684A: Merck
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- M 6223: Merck
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- TSRF 786C: Tasrif Pharmaceutical
- Drug profiles in the detailed report…..
- Inactive Products
- TIGIT Inhibitors Key Companies
- TIGIT Inhibitors Key Products
- TIGIT Inhibitors- Unmet Needs
- TIGIT Inhibitors- Market Drivers and Barriers
- TIGIT Inhibitors- Future Perspectives and Conclusion
- TIGIT Inhibitors Analyst Views
- TIGIT Inhibitors Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/tigit-inhibitors-pipeline-insight